Company Research Report: Thuja Capital Management BV

Company Overview

• Name: Thuja Capital Management BV

• Mission: Investments in healthcare ventures with lasting impact for patients and society.

• Founded: No information is available.

• Key People:

• Eline van Beest, Operational Partner

• Tyler Hayes, Principal

• Eleanor Price, Associate

• Aartie Nanda, Office & Communication Manager

• Headquarters: LSI Building, Yalelaan 62, 3584 CM Utrecht, The Netherlands

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For:

• Focusing on healthcare innovation from start-up to scale-up.

• Building and accelerating ventures in therapeutics and medical devices.

• Supporting the development of novel therapies for unmet medical needs.

Products and Services

Investment Portfolio

Thuja Capital Management BV manages several venture capital funds with a focus on therapeutics and medical devices technology. Here are some of the key companies in their active portfolio:

1. Alesta Therapeutics

• Founded: 2021

• Location: Leiden

• Focus: Developing novel small molecules for tRNA disorders like Charcot-Marie-Tooth disease.

2. Alveron Pharma

• Technology: Coagulation platform technology using cyclodextrin-based anticoagulant reversal drugs.

3. Artica Therapeutics

• Focus: Developing covalent small molecules for autoimmune and inflammatory disorders. Founded by Tjeerd Barf, Arwin Ridder, and Prof. Ad IJzerman.

4. AstriVax

• Development: Vaccines for yellow fever, rabies, and chronic hepatitis B using a thermostable vaccine platform.

5. ATRO Medical

• Product: Trammpolin® meniscus prosthesis to relieve pain and restore mobility in damaged knees.

6. CardiacBooster

• Focus: Developing a novel percutaneous left ventricular assist device for heart support during high-risk procedures and cardiogenic shock.

7. Cristal Therapeutics

• Technology: CriPec® platform for targeted nanomedicines, focusing on cancer treatments.

8. EsoBiotec

• Founded: 2021

• Focus: Preclinical stage technologies enabling immune effector cell engineering for cancer treatment.

9. FundaMental Pharma

• Focus: Developing small molecule inhibitors for neurodegenerative diseases like ALS and Huntington's Disease.

10. Gradient Denervation Technologies

• Product: Catheter device for pulmonary hypertension treatment via ultrasound-based technology.

11. Indigo Diabetes

• Product: Developing affordable diabetes management through novel glucose sensor technology.

12. InnoSIGN

• Product: OncoSIGNal mRNA-based tests for cancer treatment to predict drug responses.

13. NutriLeads

• Focus: Developing plant-derived food ingredients with proven health benefits.

14. Pan Cancer T

• Founded: 2020

• Focus: T cell receptor therapies for solid tumors, leveraging over two decades of adoptive T cell therapy research.

15. Salvia BioElectronics

• Product: Bioelectronics solutions for treating severe neurological disorders via non-invasive electrical impulses.

16. Synerkine Pharma

• Focus: Novel fusion proteins for the treatment of pain, using a fusion protein of IL4 and IL10.

17. Tacalyx

• Focus: Antibody-based therapeutics targeting Tumor Associated Carbohydrate Antigens for cancer treatment.

Recent Developments

• Late 2024: Thuja is a proud supporter of the EU Life Sciences ESG Knowledge Project, participating in the release of a 2025 questionnaire for investors.

• Synerkine Pharma: Received European Orphan Drug Designation for SK-01 to treat Complex Regional Pain Syndrome in September 2024.

• Tacalyx: Thuja led the extension of Tacalyx's seed financing in June 2024.

• FundaMental Pharma: Appointed Dr. Dirk Beher as CEO in April 2024 and announced a groundbreaking Proof-of-Concept Study publication in February 2024.

• Alveron Pharma and Cristal Therapeutics: No recent developments mentioned.

• Release of 2023 Impact & ESG Annual Report: Announced on October 14, 2024.

• Promotion and Appointments: Eleanor Price promoted to Associate in January 2024; introduction of new personnel including Eline van Beest and Tyler Hayes.

Overall, Thuja Capital Management BV continues to expand its impact in the life sciences sector with a strong focus on healthcare innovations aimed at addressing significant unmet medical needs.